Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 in Patients With Mild to Moderate Systemic Lupus Erythematosus.

Trial Profile

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 in Patients With Mild to Moderate Systemic Lupus Erythematosus.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 May 2019

At a glance

  • Drugs Solcitinib (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 May 2019 This trial is completed in Estonia according to European Clinical Trials Database record.
    • 31 Aug 2018 Biomarkers information updated
    • 01 Nov 2016 Results published in the Lupus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top